Spine News and Research

RSS

Survey investigates procurement procedures, expenditures and consumption of medical devices

Centralised purchasing of medical devices does not reduce prices and medical devices are often undervalued as analyses focus only on the short-term financial and economic perspectives.

16 Apr 2010

Smith & Nephew's ALLEVYN highlighted at SAWC

The Advanced Wound Management Division of Smith & Nephew, Inc., a subsidiary of Smith & Nephew plc invites those attending the upcoming Symposium on Advanced Wound Care to visit the Smith & Nephew booth 301, to see the ALLEVYN™ difference with its unique triple-action technology and dynamic moisture control.

16 Apr 2010

Alphatec Holdings prices underwritten public offering of common stock

Alphatec Holdings, Inc., the parent company of Alphatec Spine, Inc., a medical device company that designs, develops, manufactures and markets products for the surgical treatment of spine disorders, with a focus on treating conditions related to the aging spine, announced that is has priced an underwritten public offering of 16,000,000 shares of common stock, consisting of 8,000,000 shares to be sold by the Company and 8,000,000 shares to be sold by a selling shareholder, HealthpointCapital Partners, L.P., at a price to the public of $5.00 per share.

16 Apr 2010

Sunlight Research's Stem Cell Industry Report analyzes U.S. Stem Cell patent landscape

Sunlight Research – The Source for Patent Analysis, today announced the release of its comprehensive Stem Cell Industry Report analyzing the U.S. Stem Cell patent landscape. Stem cells are particularly attractive for use as cellular therapies because they self-renew and have the capacity to produce many different specialized cell types.

16 Apr 2010

Watson Laboratories' ANDA for generic Toprol XL tablets receives FDA approval

Watson Pharmaceuticals, Inc., today announced that its subsidiary, Watson Laboratories, Inc. - Florida, has received approval from the United States Food and Drug Administration on its Abbreviated New Drug Application for metoprolol succinate extended-release tablets USP in the 100 and 200 mg strengths, the generic equivalent to AstraZeneca's Toprol XL® tablets.

16 Apr 2010

New iVAS inflatable vertebral augmentation system released for VCFs

Stryker's Interventional Spine business unit today announced the release of its iVAS inflatable vertebral augmentation system, a minimally invasive device cleared for use in treating vertebral compression fractures.

15 Apr 2010

biospace med raises $18M to accelerate market penetration of EOS imaging system in North America and Europe

biospace med announced today that it has raised $18 million to accelerate market expansion in North America and Europe of the company's FDA-cleared EOS ultra-low-dose 2D/3D imaging system.

15 Apr 2010

Biomet's third fiscal quarter net sales increase 9%

Biomet, Inc. announced today financial results for its third fiscal quarter ended February 28, 2010.

15 Apr 2010

Investment group acquires Arbor Pharmaceuticals

Arbor Pharmaceuticals, a specialty pharmaceutical company focused on pediatric medicine, announced today that an investment group led by Jason Wild of JW Asset Management, LLC and Edward Schutter has acquired the company.

15 Apr 2010

High level of microRNAs found in patients with high-risk multiple myeloma

Multiple myeloma researchers at the University of Arkansas for Medical Sciences (UAMS) recently discovered that widespread activity of a specific class of genes can identify aggressive, or high-risk, cases of the disease.

13 Apr 2010

NeoStem opens new adult stem cell collection center in Austin, TX

NeoStem, Inc., an international biopharmaceutical company with operations in the U.S. and China, announced the launch of the newest adult stem cell collection center in its network to open in Austin, TX on April 15, 2010.

13 Apr 2010

Gilead Sciences doses first patient in Quad Phase III clinical program

Gilead Sciences, Inc. today announced that it has dosed the first patient in the Phase III clinical program evaluating its investigational fixed-dose, single-tablet "Quad" regimen of elvitegravir, cobicistat (formerly GS 9350), emtricitabine and tenofovir disoproxil fumarate.

13 Apr 2010

Alphatec Holdings proposes 8 million common stock public offering

Alphatec Holdings, Inc., the parent company of Alphatec Spine, Inc., a medical device company that designs, develops, manufactures and markets products for the surgical treatment of spine disorders, with a focus on treating conditions related to the aging spine, announced that it is offering to sell 8,000,000 primary shares of its common stock and a selling shareholder, HealthpointCapital Partners, L.P., is offering 8,000,000 shares of Alphatec common stock in an underwritten public offering.

12 Apr 2010

Alphatec Spine's first-quarter preliminary consolidated revenues up 25.6%

Alphatec Holdings, Inc., the parent company of Alphatec Spine, Inc., a medical device company that designs, develops, manufactures and markets products for the surgical treatment of spine disorders, with a focus on treating conditions related to the aging spine, announces today that, based on preliminary financial data, the Company will report record consolidated quarterly revenues of approximately $38.4 million for the first quarter 2010, an increase of 25.6% from the $30.6 million reported for the first quarter 2009.

12 Apr 2010

U-M Medical School researchers earn $366M in NIH research funding in fiscal year 2009

University of Michigan Medical School physicians and scientists earned more than $366 million in National Institutes of Health research funding in federal fiscal year 2009, according to NIH data. In all, the School's faculty brought in more than $435 million in research funding from all sources in U-M fiscal year 2009.

12 Apr 2010

UNC Charlotte researcher improves lives of families and children affected by birth defects

Birth defects remain a leading cause of death in the first year of life. According to the March of Dimes, every 3 to 4 minutes a baby is born with a birth defect in the United States. About 1 in every 33 infants is affected by birth defects.

8 Apr 2010

Saint Mary's and Sierra Neurosurgery Group partner to create Nevada's first Brain Tumor Center

Saint Mary's and Sierra Neurosurgery Group have partnered to create the region's first Brain Tumor Center in an effort to speed up the time between diagnosis and treatment.

8 Apr 2010

Sigma-Aldrich, Boehringer Ingelheim Pharma enter distribution agreement for RESOMER polymers

Sigma-Aldrich® announced today it has entered into a distribution agreement with Boehringer Ingelheim Pharma GmbH & Co. KG, Germany, to offer its portfolio of RESOMER biodegradable polylactide (PLA) and poly(lactide-co-glycolide) (PLGA) polymers to the research community.

8 Apr 2010

Women need to be educated on osteoporosis risk factors and treatment: Study

Underscoring what researchers call a serious global public health concern, results from a new study led by Columbia University Medical Center reveal that many women at an elevated level of risk for osteoporosis-associated fractures fail to perceive the implications of the risk factors.

8 Apr 2010

MAP Pharmaceuticals initiates PD trial comparing LEVADEX to IV DHE

MAP Pharmaceuticals, Inc. today announced that the Company initiated a pharmacodynamics (PD) trial to compare the acute effect of LEVADEX™ orally inhaled migraine therapy to intravenous dihydroergotamine mesylate (IV DHE) and placebo on pulmonary artery pressure as measured by echocardiography.

8 Apr 2010